Compugen (CGEN) Competitors $1.53 +0.01 (+0.66%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CGEN vs. PROK, DNA, ANNX, ATXS, HUMA, PRTC, ANAB, MREO, CRMD, and XERSShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include ProKidney (PROK), Ginkgo Bioworks (DNA), Annexon (ANNX), Astria Therapeutics (ATXS), Humacyte (HUMA), PureTech Health (PRTC), AnaptysBio (ANAB), Mereo BioPharma Group (MREO), CorMedix (CRMD), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Compugen vs. ProKidney Ginkgo Bioworks Annexon Astria Therapeutics Humacyte PureTech Health AnaptysBio Mereo BioPharma Group CorMedix Xeris Biopharma Compugen (NASDAQ:CGEN) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, community ranking, risk and institutional ownership. Is CGEN or PROK more profitable? Compugen has a net margin of 2.67% compared to ProKidney's net margin of 0.00%. Compugen's return on equity of 2.62% beat ProKidney's return on equity.Company Net Margins Return on Equity Return on Assets Compugen2.67% 2.62% 1.36% ProKidney N/A N/A -10.24% Which has more risk and volatility, CGEN or PROK? Compugen has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Do insiders and institutionals believe in CGEN or PROK? 12.2% of Compugen shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 41.5% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor CGEN or PROK? Compugen received 300 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 64.30% of users gave Compugen an outperform vote while only 57.14% of users gave ProKidney an outperform vote. CompanyUnderperformOutperformCompugenOutperform Votes30864.30% Underperform Votes17135.70% ProKidneyOutperform Votes857.14% Underperform Votes642.86% Which has stronger valuation and earnings, CGEN or PROK? Compugen has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$59.85M2.28-$18.75M$0.0276.50ProKidneyN/AN/A-$35.47M-$0.55-2.75 Does the media prefer CGEN or PROK? In the previous week, ProKidney had 3 more articles in the media than Compugen. MarketBeat recorded 3 mentions for ProKidney and 0 mentions for Compugen. ProKidney's average media sentiment score of 0.71 beat Compugen's score of 0.00 indicating that ProKidney is being referred to more favorably in the news media. Company Overall Sentiment Compugen Neutral ProKidney Positive Do analysts prefer CGEN or PROK? Compugen currently has a consensus target price of $4.00, indicating a potential upside of 161.44%. ProKidney has a consensus target price of $4.50, indicating a potential upside of 198.01%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ProKidney 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 SummaryCompugen beats ProKidney on 11 of the 17 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$136.53M$2.94B$5.13B$9.07BDividend YieldN/A1.90%4.93%4.23%P/E Ratio76.5046.7389.7417.19Price / Sales2.28415.011,115.29116.95Price / CashN/A182.1042.8237.86Price / Book2.103.894.774.78Net Income-$18.75M-$42.21M$120.04M$225.60M7 Day Performance-4.97%-2.15%-1.92%-1.23%1 Month Performance5.52%4.20%11.46%3.36%1 Year Performance-12.07%18.39%30.52%16.60% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen1.5938 of 5 stars$1.53+0.7%$4.00+161.4%-17.3%$136.53M$59.85M76.5068PROKProKidney2.0368 of 5 stars$1.91+6.1%$4.50+136.2%-15.6%$555.62MN/A-3.553Gap DownDNAGinkgo Bioworks0.5512 of 5 stars$9.64+2.1%$4.58-52.5%N/A$554.11M$251.46M-0.721,218Gap DownANNXAnnexon2.1121 of 5 stars$5.17+16.4%$15.80+205.6%+81.6%$551.09MN/A-4.9060Analyst ForecastNews CoverageGap DownATXSAstria Therapeutics2.0771 of 5 stars$9.70+1.9%$25.60+163.9%+58.0%$547.37MN/A-4.5630News CoverageHUMAHumacyte3.3459 of 5 stars$4.21+2.7%$13.00+208.8%+69.3%$529.87M$1.57M-3.06150Analyst ForecastGap UpPRTCPureTech Health1.9898 of 5 stars$22.10+8.6%$45.00+103.6%+3.8%$529.12M$3.33M0.00100Gap DownHigh Trading VolumeANABAnaptysBio2.3125 of 5 stars$17.11+9.7%$45.09+163.5%-25.4%$520.66M$17.16M-2.80100Analyst ForecastMREOMereo BioPharma Group2.0953 of 5 stars$3.35-10.4%$7.40+120.9%+68.3%$519.74M$1M0.0040High Trading VolumeCRMDCorMedix1.8468 of 5 stars$8.47+1.1%$15.20+79.5%+147.0%$513.93M$12.26M-10.3530Analyst ForecastNews CoveragePositive NewsXERSXeris Biopharma3.6033 of 5 stars$3.41+4.0%$4.87+42.7%+73.6%$508.36M$163.91M-7.29290News CoveragePositive News Related Companies and Tools Related Companies ProKidney Alternatives Ginkgo Bioworks Alternatives Annexon Alternatives Astria Therapeutics Alternatives Humacyte Alternatives PureTech Health Alternatives AnaptysBio Alternatives Mereo BioPharma Group Alternatives CorMedix Alternatives Xeris Biopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGEN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
